Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.96 (1y: -47%)
Market Cap 112.1 M P/E(ttm)
Enterprise Value 48.76 M P/B
ONTY- NAS (USA)
Oncothyreon, Inc.
Not Rated
Top Ranked Predictable Companies
$1.96
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
» ONTY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ONTY Guru Trades in Q2 2012

Jim Simons 154,882 sh (New)
Murray Stahl 28,333 sh (unchged)
Andreas Halvorsen 3,256,615 sh (-0.17%)
» More
Q3 2012

ONTY Guru Trades in Q3 2012

Andreas Halvorsen 3,268,715 sh (+0.37%)
Murray Stahl 28,333 sh (unchged)
Jim Simons Sold Out
» More
Q4 2012

ONTY Guru Trades in Q4 2012

Jim Simons 528,500 sh (New)
Andreas Halvorsen 3,361,315 sh (+2.83%)
Murray Stahl 28,333 sh (unchged)
» More
Q1 2013

ONTY Guru Trades in Q1 2013

Jean-Marie Eveillard 200,000 sh (New)
Jim Simons 1,003,697 sh (+89.91%)
Andreas Halvorsen 3,700,115 sh (+10.08%)
Murray Stahl 28,333 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 New Buy$1.86 - $2.35 $ 1.96-6%200000
Jean-Marie Eveillard 2012-03-31 Sold Out 0.0033%$4.16 - $8.96 $ 1.96-69%0
Jean-Marie Eveillard 2011-12-31 Add 33.33%$5.84 - $8.25 $ 1.96-71%100000
Jean-Marie Eveillard 2011-09-30 Reduce -66.67%0.01%$5.95 - $10.2 $ 1.96-74%75000
Jean-Marie Eveillard 2011-06-30 New Buy0.01%$3.8 - $9.43 $ 1.96-66%225000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
EV-to-EBIT 0.4
ONTY's EV-to-EBIT is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. ONTY: 0.4 )
ONTY' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.4

Valuation & Return

vs
industry		 vs
history

Business Description

Oncothyreon Inc. was incorporated in 1985 in Canada under the name Biomira Inc., or Biomira. The Company is a clinical-stage biopharmaceutical company focused mainly on the development of therapeutic products for the treatment of cancer. The company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. It is advancing its product candidates through in-house development efforts and strategic collaborations. The company's lead product candidate is Stimuvax, which is a cancer vaccine currently in Phase 3 development for non-small cell lung cancer, or NSCLC. It has granted an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of Stimuvax. The company's pipeline of product candidates is comprised of cancer vaccines and small molecules. Its cancer vaccines attack cancer cells by stimulating the immune system, while its small molecule product candidates inhibit critical cancer-related pathways. The resulting product pipeline provides it with opportunities to diversify risk, develop new therapies and establish strategic partnerships. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. The Company competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:3O6.Germany
» More Articles for ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial